SU1642384A1 - Method for determination of efficacy of phosphobion and verapamil in arresting an attack of paroxysmal supraventricular tachycardia - Google Patents

Abstract

This invention relates to cardiology and electrophysiology; in particular, to methods for assessing the individual efficacy of entiarrhythmic drugs. The purpose of the invention is to improve accuracy. Prior to the administration of antiarrhythmic drugs, an electrophysiological examination of the heart is carried out, for example, through the esophagus. Then an attack of supraventricular paroxysmal tachycardia is triggered. To stop it, a phosphobion or verapamil is administered intravenously in a specific amount. After normal heart rhythm is restored, the study of agrioventricular conduction is repeated. Based on the data obtained, a decrease in atrioventricular conductivity, as well as its percentage decrease depending on the initial level is determined, and the reason for the absence of the effect is determined from their results. The method allows an individual selection of anti-arrhythmic drugs. 8 (L

Description

The invention relates to cardiology and electrophysiology and can be used to evaluate the individual efficacy of antiarrhythmic drugs.

The purpose of the invention is to improve accuracy.

The method is carried out as follows.

Prior to the administration of antiarrhythmic drugs, an electrophysiological examination of the heart is carried out for

determining the initial state of the atrioventricular (AV) conduction and, by frequent stimulation of the atria, provoke an attack of supravel paroxysmal tachycardia. To stop it, a phosphobion is administered intravenously in an amount of 0.01-0.25 mg / kg body weight (in particular, an average of 10 mg) or verapamil at a dose of 0.075-0.15 mg / kg body weight (in particular, an average 10 mg). If the tachycardia on the background of the action of the drug is not

stops, it is stopped by frequent stimuli; auricles After the normal heart rhythm has been restored, the AV-reducible study is re-performed. On the basis of the data obtained, the decrease in the AV conductivity (Wenckebach point) in beats per minute is determined, as well as its percentage decrease depending on the initial level. In cases where the decrease in AV conduction due to phosphobion is less by 11.6-13.2%, and for verapamil by 10.2-12%, the dose of drugs is increased.

For example. Patient S., 21 g. To stop a tachycardia attack, a phosphobion was administered intravenously at a dose of 10 mg, but to no avail. The attack was stopped only with an electric defibrillation of the heart.

To determine the cause of the absence of the phosphobion effect, an electrophysiological study of the heart was carried out through the esophagus. An attack of supraventricular paroxysmal tachycardia was provoked. To stop it intravenously without diluting during JO, 10 mg of phosphobion was injected. When observed for 5 min, the seizure did not cease, so it was discontinued by frequent stimulation with a frequency of 200 imp. / Min.

0

five

Q

0

five

Against the background of a restored sinus rhythm, the state of AV conduction was re-examined, the decrease of which under the action of a phosphobion was only 6–3%. A tachycardia attack was re-provoked and 20 mg of phosphobion was injected to stop it. Within 30 seconds, stable sinus rhythm was restored. The AV-conduction study showed that it decreased by 12.5%.

The method allows individual selection of antiarrhythmic agents.

Claims (1)

Invention Formula A method for determining the efficacy of phosphobion and verapamil for relieving an attack of supraventricular paroxysmal tachycardia by examining atrioventricular conduction using electrical stimulation, characterized in that, in order to increase accuracy, a provocation of the attack is performed with the help of transesophageal stimulation, after which a phosphobion or verapamel is administered, and the effectiveness is determined by reducing atrioventricular conductivity by 11.6-13.2% for the phosphobion and by 10.2-12, 0% dl verapamil.